Xtant Medical Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Xtant Medical Holdings is Sean Browne, benoemd in Oct2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.71M, bestaande uit 35% salaris en 65% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.96% van de aandelen van het bedrijf, ter waarde $ 717.47K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 3.7 jaar.

Belangrijke informatie

Sean Browne

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris	35.0%
Dienstverband CEO	5.1yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

Mar 02

Analyse CEO-vergoeding

Hoe is Sean Browne's beloning veranderd ten opzichte van Xtant Medical Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$2m
Dec 31 2023	US$2m	US$600k	US$660k
Sep 30 2023	n/a	n/a	US$3m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$1m	US$600k	-US$8m
Sep 30 2022	n/a	n/a	-US$9m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$831k	US$590k	-US$5m
Sep 30 2021	n/a	n/a	-US$3m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$5m	US$604k	-US$7m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$8m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$2m	US$116k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.71M ) Sean } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 645.01K ).

Compensatie versus inkomsten: De vergoeding van Sean is gestegen terwijl het bedrijf verliesgevend is.

CEO

Sean Browne (58 yo)

5.1yrs

Tenure

US$1,712,158

Compensatie

Mr. Sean E. Browne serves as President and Chief Executive Officer of Xtant Medical Holdings, Inc. since October 7, 2019 and its Director since October 30, 2019. Mr. Browne served as Chief Revenue Officer...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sean Browne	President	5.1yrs	US$1.71m	0.96% $ 717.5k
Mark Schallenberger	Chief Operations Officer	1.8yrs	US$1.19m	0.016% $ 12.0k
Scott Neils	Chief Financial Officer	2.8yrs	US$766.53k	0.13% $ 94.9k
Catherine Lundy	Vice President of Human Resources	10.2yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

40yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van XTNT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sean Browne	President	5.1yrs	US$1.71m	0.96% $ 717.5k
John Bakewell	Independent Director	6.8yrs	US$284.31k	0.32% $ 242.2k
Lori Mitchell-Keller	Independent Director	1.5yrs	US$276.91k	0.14% $ 103.1k
Jonn Beeson	Independent Director	1.5yrs	US$286.79k	0.77% $ 576.4k
Robert McNamara	Independent Director	6.8yrs	US$284.31k	0.32% $ 241.3k
Stavros Vizirgianakis	Chairman	2.3yrs	US$401.46k	4.32% $ 3.2m

3.7yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van XTNT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Xtant Medical Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024

Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors

Xtant Medical Holdings, Inc. Announces Executive Changes

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023

Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023

Less than half of directors are independent

Recent updates

Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Consensus EPS estimates fall by 11%

New minor risk - Profitability

Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System

Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus

Xtant Medical Holdings, Inc. announced that it has received $5 million in funding

New minor risk - Shareholder dilution

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024

Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024

New minor risk - Profitability

Price target increased by 27% to US$2.35

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024

Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds

Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds

Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Consensus revenue estimates increase by 17%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023

Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Consensus EPS estimates fall by 17%, revenue upgraded

Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Consensus EPS estimates upgraded to US$0.06 loss

Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xtant Medical Holdings, Inc. Announces Executive Changes

Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021)

Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023

Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021)

Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022

Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding

Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021)

Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020)

Shareholders Are Thrilled That The Xtant Medical Holdings (NYSEMKT:XTNT) Share Price Increased 186%

New 90-day high: US$4.26

Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019)

Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding

Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: US$1.84

New 90-day high: US$1.52

Third quarter earnings released